Investigative ophthalmology & visual science · 1998
Use of topical cyclosporin A in a primary Sjögren's syndrome mouse model.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tsubota K, Saito I, Ishimaru N, Hayashi Y
Аннотация
PURPOSE: A new animal model, the NFS/sld mutant mouse, was used for primary Sjögren's syndrome to investigate the efficacy of topical and systemic cyclosporin A (CyA) in preventing inflammation of the exocrine glands.
METHODS: Cyclosporin A was applied topically (0.01% and 0.1%, three times a day) or administered orally (10 mg/kg and 100 mg/kg, once a day) to mice from 6 to 16 weeks of age, after which the mice were killed.
RESULTS: Topical CyA reduced lacrimal gland and submandibular gland inflammation without causing pathologic changes in other organs. Flow cytometry showed that CD44 expression of CD4 T cells from the submandibular lymph nodes was downregulated, whereas that of Mel14+ was upregulated. Using a reverse transcription-polymerase chain reaction assay, we determined that topical CyA significantly decreased the expression of mRNA of IL-2 and T-cell receptor-constant beta-chain.
CONCLUSIONS: Topical CyA may be clinically useful in reducing the lymphocyte infiltration of lacrimal glands associated with Sjögren's syndrome.
METHODS: Cyclosporin A was applied topically (0.01% and 0.1%, three times a day) or administered orally (10 mg/kg and 100 mg/kg, once a day) to mice from 6 to 16 weeks of age, after which the mice were killed.
RESULTS: Topical CyA reduced lacrimal gland and submandibular gland inflammation without causing pathologic changes in other organs. Flow cytometry showed that CD44 expression of CD4 T cells from the submandibular lymph nodes was downregulated, whereas that of Mel14+ was upregulated. Using a reverse transcription-polymerase chain reaction assay, we determined that topical CyA significantly decreased the expression of mRNA of IL-2 and T-cell receptor-constant beta-chain.
CONCLUSIONS: Topical CyA may be clinically useful in reducing the lymphocyte infiltration of lacrimal glands associated with Sjögren's syndrome.
Предметные рубрики MeSH
Administration, OralAdministration, TopicalAnimalsCD4-Positive T-LymphocytesCyclosporineDNA PrimersDisease Models, AnimalFemaleFlow CytometryHyaluronan ReceptorsImmunoenzyme TechniquesImmunosuppressive AgentsInterleukin-2Lacrimal ApparatusMiceMice, Inbred BALB CMice, Mutant StrainsOphthalmic SolutionsPolymerase Chain ReactionRNA, MessengerReceptors, Antigen, T-Cell, alpha-betaSjogren's SyndromeSubmandibular Gland